Linked Life Data

11898553

Source:http://linkedlifedata.com/resource/pubmed/id/11898553

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2002-3-18
pubmed:abstractText
In the past 2 years, substantive advances in therapy for Alzheimer's disease (AD) have occurred. The nature of the effects of cholinesterase inhibitors has been refined with the publication of several studies that have examined different aspects of the symptomatology of AD. Breakthroughs in the basic science of Alzheimer's disease have led to new insights into potential therapeutic strategies targeted at the secretases involved in the metabolism of the Alzheimer precursor protein. An immunization approach, in which the beta-amyloid protein itself was used as the immunizing agent, has also been presented and independently validated. Other areas of investigation with disappointing results, such as estrogen replacement therapy, anti-inflammatory approaches, and several other therapeutic agents, are also reviewed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1528-4042
pubmed:author
pubmed:issnType
Print
pubmed:volume
1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
428-34
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Pharmacotheraphy for Alzheimer's disease.
pubmed:affiliation
Department of Neurology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. knopman@mayo.edu
pubmed:publicationType
Journal Article, Review